Profile of anterior gradient 3 (AGR3) mRNA expression and serum levels in benign and malignant breast tumors.
Breast Dis
; 40(S1): S39-S43, 2021.
Article
en En
| MEDLINE
| ID: mdl-34057117
ABSTRACT
BACKGROUND:
Benign and malignant breast tumors are the most commonly diagnosed tumor in females. Early and accurate diagnosis of malignancy is essential for effective breast cancer treatment. Human anterior gradient 3 (AGR3) has been suggested as a potential biomarker for the early detection and prognostic determination of breast cancer.OBJECTIVE:
This study profiles AGR3 mRNA expression and serum protein levels in patients with benign and malignant breast tumors.METHODS:
A case-control study was conducted on 40 benign and 40 malignant breast tumor patients in Makassar, Indonesia. AGR3 mRNA and protein were detected using qRT-PCR and ELISA, respectively.RESULTS:
This study found significantly higher AGR3 mRNA expression in benign than malignant breast tumors using qRT-PCR (p < 0.001). In contrast, ELISA revealed no significant difference between AGR3 serum protein levels in benign and malignant breast tumors (p = 0.507).CONCLUSIONS:
AGR3 is associated with non-aggressive tumors and could be used as a marker for less aggressive breast tumors.Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Neoplasias de la Mama
/
ARN Mensajero
/
Proteínas Portadoras
/
Proteínas de Neoplasias
Tipo de estudio:
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
/
Screening_studies
Límite:
Adult
/
Female
/
Humans
/
Middle aged
Idioma:
En
Año:
2021
Tipo del documento:
Article